| S1191 |
Fulvestrant (ICI-182780)
|
Fulvestrant is an estrogen receptor (ER) antagonist with IC50 of 0.94 nM in a cell-free assay. Fulvestrant also induces autophagy and apoptosis and has antitumor activity.
|
-
Nat Genet, 2025, 57(6):1452-1462
-
J Clin Invest, 2025, e188839
-
Cell Rep Med, 2025, 6(7):102192
|
|
| S7827 |
4-Hydroxytamoxifen (Afimoxifene)
|
4-Hydroxytamoxifen (Afimoxifene) is the active metabolite of tamoxifen and a selective estrogen receptor (ER) modulator that is widely used in the therapeutic and chemopreventive treatment of breast cancer. It activates on-target modification frequency for intein-Cas9 variants.
|
-
Signal Transduct Target Ther, 2025, 10(1):97
-
Cell Death Differ, 2025, 10.1038/s41418-025-01514-7
-
Cell Rep, 2025, 44(5):115652
|
|
| S8956 |
(Z)-4-Hydroxytamoxifen
|
(Z)-4-Hydroxytamoxifen ((Z)-4-OHT, trans-4-Hydroxytamoxifen, 4-Monohydroxytamoxifen) is a selective modulator of estrogen receptor (SERM) with IC50 of 3.3 nM for the [3H]oestradiol binding to oestrogen receptor.
|
-
Mol Syst Biol, 2025, 10.1038/s44320-025-00104-6
-
Oncogene, 2025, 10.1038/s41388-025-03367-3
-
bioRxiv, 2025, 2024.12.19.629395
|
|
| S8687 |
MPP dihydrochloride
|
Methyl-piperidino-pyrazole (MPP) dihydrochloride is a highly selective antagonist for estrogen receptor alpha (ERα), with an affinity 200 times greater than for estrogen receptor beta (ERβ). It inhibits 17β-estradiol binding to ERα by inducing conformational changes that alter the receptor’s binding site and also increases the energy required for genistein's interaction with ERα.
|
-
Drug Des Devel Ther, 2024, 18:4943-4960
|
|
| S9629 |
Elacestrant (RAD1901) Dihydrochloride
|
Elacestrant (RAD1901) Dihydrochloride is an orally available selective estrogen receptor degrader (SERD) with IC50 of 48 nM and 870 nM for ERα and ERβ, respectively.
|
-
Front Oncol, 2022, 12:857590
|
|
| S9862 |
Vepdegestrant (ARV-471)
|
Vepdegestrant (ARV471) is an orally bioavailable estrogen receptor-targeting (ER-targeting) PROTAC for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer.
|
|
|
| S1238 |
Tamoxifen
|
Tamoxifen is an orally active, selective estrogen receptor modulator (SERM) which exhibits both estrogenic agonist and antagonist effects. It blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity.
|
-
Cell Discov, 2025, 11(1):89
-
Nat Genet, 2025, 57(9):2192-2202
-
Cell Metab, 2025, 37(8):1715-1731.e11
|
|
| S1709 |
17β-Estradiol
|
Estradiol (17β-estradiol, β-Estradiol, E2, 17β-Oestradiol) is a human sex hormone and steroid, and the primary female sex hormone. Estradiol upregulates IL-6 expression through the estrogen receptor β (ERβ) pathway.
|
-
Cancer Cell, 2025, 43(5):891-904.e10
-
Nat Commun, 2025, 16(1):758
-
Cell Rep Med, 2025, 6(7):102192
|
|
| S2606 |
Mifepristone (RU-486)
|
Mifepristone is a remarkably active antagonist of progesterone receptor and glucocorticoid receptor with IC50 of 0.2 nM and 2.6 nM, respectively. Mifepristone promotes cell autophagy and apoptosis, decreases Bcl-2 level and increases Beclin1 level, accompanied by weakened interaction between Bcl-2 and Beclin1.Mifepristone (RU486) can be used to induce animal models of Spontaneous Abortion.
|
-
Pharmacol Res, 2025, 215:107696
-
Cell Death Dis, 2025, 16(1):237
-
J Virol, 2025, 99(2):e0147224
|
|
| S1972 |
Tamoxifen Citrate
|
Tamoxifen Citrate is a selective estrogen receptor modulator (SERM). This compound is also a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. It induces apoptosis and autophagy.
|
-
bioRxiv, 2025, 2025.07.21.666025
-
bioRxiv, 2024, 2023.05.10.540211
-
EMBO Rep, 2023, 24(5):e55835
|
|